atorvastatin + Vitamin E
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Fatty Liver
Conditions
Fatty Liver, Dyslipidemias, Diabetes Mellitus
Trial Timeline
May 1, 2013 → Dec 1, 2016
NCT ID
NCT01720719About atorvastatin + Vitamin E
atorvastatin + Vitamin E is a approved stage product being developed by Pfizer for Fatty Liver. The current trial status is unknown. This product is registered under clinical trial identifier NCT01720719. Target conditions include Fatty Liver, Dyslipidemias, Diabetes Mellitus.
What happened to similar drugs?
5 of 11 similar drugs in Fatty Liver were approved
Approved (5) Terminated (3) Active (4)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01720719 | Approved | UNKNOWN |
Competing Products
20 competing products in Fatty Liver
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lanifibranor | Inventiva | Phase 2 | 29 |
| Low Dose REN001 + High Dose REN001 | OnKure Therapeutics | Phase 1 | 19 |
| GODEX + Placebo | Celltrion | Phase 3 | 47 |
| placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo | AstraZeneca | Phase 2 | 35 |
| AZ compound | AstraZeneca | Phase 2 | 27 |
| Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + Placebo | AstraZeneca | Phase 2 | 35 |
| AZD7503 Intervention | AstraZeneca | Phase 1 | 29 |
| metformin | Merck | Phase 2/3 | 34 |
| Efinopegdutide + Semaglutide + Placebo | Merck | Phase 2 | 35 |
| MK-4074 200 mg + Placebo for MK-4074 + Pioglitazone hydrochloride 30 mg + Placebo for pioglitazone hydrochloride | Merck | Phase 1 | 29 |
| Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mL | Merck | Phase 2 | 35 |
| LYS006 + Tropifexor | Novartis | Phase 2 | 27 |
| LJN452 | Novartis | Phase 1 | 29 |
| LCQ908 + placebo | Novartis | Phase 2 | 35 |
| Orlistat (Xenical) | Roche | Approved | 43 |
| Xenical, Pegasys, Copegus | Roche | Approved | 43 |
| Placebo + RO5093151 | Roche | Phase 1 | 29 |
| AMG 609 + Placebo | Amgen | Phase 1 | 29 |
| Glucagon | Novo Nordisk | Pre-clinical | 26 |
| Blood samples | Novo Nordisk | Pre-clinical | 18 |